Figure 2From: A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults Solicited local symptoms of any grade and grade 3 severities, following two doses of the AS03 A -adjuvanted A/Indonesia/5/2005 (H5N1) vaccine, given 21 days apart.Back to article page